Emulation of a phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis First published 22/01/2025 Last updated 22/01/2025 EU PAS number:EUPAS1000000450 Study Ongoing